Feature | November 13, 2013

Lack of Off-Label Promotion Guidance Leaves Companies in the Dark

LeClairRyan attorney offers suggestions for pharmaceutical and medical device companies targeted by regulators

November 13, 2013 – No law prevents doctors from freely prescribing U.S. Food and Drug Administration (FDA)-approved drugs and devices for off-label uses, yet regulators continue to aggressively pursue civil and criminal enforcement of perceived violations, warns Patrick J. Hurd, senior counsel with LeClairRyan in Washington, D.C. and Norfolk, Va. in the November 2013 edition of Westlaw Journal Pharmaceutical.

His article, “Charting a Prudent Course on Off-Label Promotion of Drugs and Devices,” also appeared in the September 10, 2013 edition of Westlaw Journal Medical Devices.

The promotional materials used by drug and device companies are among the most heavily regulated communications in the world, notes Hurd, adding that in fiscal year 2012 alone, the Justice Department recovered nearly $2 billion in cases alleging false claims for drugs and medical devices, and obtained 14 criminal convictions and $1.5 billion in criminal fines and forfeitures under the Food, Drug and Cosmetic Act (FDCA).

But this does not necessarily mean that drug and device companies should simply refrain from ever discussing off-label uses of their products in ways that could be construed as promotional, he adds.

“This is because, taken together, three rulings from the past few years do suggest a framework for charting a prudent course on off-label promotions,” explains Hurd, a member of the firm’s BioPharma and Life Sciences Industry Team, who represents hospitals, physicians, medical device makers and other healthcare-related organizations.

The rulings, United States v. Caputo, 517 F.3d 935 (7th Cir. 2008), United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), and United States v. Harkonen, 510 F. App’x 633 (9th Cir. 2013), also help to “clarify the conditions under which the free speech clause of the First Amendment is likely to protect such discussions,” he adds.

In the Caputo case, the issue involved off-label claims about Plazlyte, a device formerly used to sterilize medical instruments. According to the government, executives from manufacturer Abtox Inc. ignored studies showing product failures and aggressively marketed the sterilizer for unsafe uses even in the face of FDA warning letters. The executives were convicted of multiple counts of fraud, sentenced to prison terms and ordered to pay restitution of $17.2 million to 144 hospitals.

The defendants appealed to the 7th U.S. Circuit Court of Appeals, arguing, among other things, that their First Amendment rights had been violated. The court rejected that argument, noting that “unless the machine itself could be sold lawfully, there were no lawful off-label uses to promote. And the jury found, by its verdicts on both the fraud-on-the-United States count and the misbranded-device counts, that the [sterilizer device] could not be sold,” Hurd writes.

In stark contrast to that, United States v. Caronia “helps illustrate the conditions under which drug and device makers can feel more confident about discussing off-label uses,” Hurd adds. In the Caronia case, a sales representative and a paid-consultant physician were charged in August 2008 with two counts of misbranding after they promoted off-label uses of the narcolepsy drug Xyrem to a government informant who was wearing a wire.

Convicted by a jury, the defendants appealed to the 2nd Circuit, arguing that the misbranding provisions in the FDCA violated the First Amendment by preventing the drug company representatives from engaging in speech related to off-label promotion. The circuit court applied the Supreme Court’s four-pronged test for protected commercial speech and concluded that the government “simply … cannot prosecute pharmaceutical manufacturers and their representatives under the FDCA for speech promoting the lawful, off-label use of an FDA-approved drug,” notes Hurd.

But a more recent case, United States v. Harkonen, highlights the potential for illegal conduct to trump any assumed protections of speech, Hurd cautions. On March 4, 2013, the 9th Circuit affirmed a trial court decision by focusing on the defendants’ fraudulent conduct in the case — issuing a press release full of false and misleading statements about off-label uses of the immune system booster Actimmune, thereby engaging in wire fraud.

While the Supreme Court has provided a four-pronged test for determining commercial speech protected by the free speech clause of the First Amendment, the court has yet to deal head on with the issue of off-label promotion and its validity, Hurd notes. Likewise, drug and device companies are still waiting for the FDA’s final, long-promised guidance on this issue. (Hearings were first held in 2009.)

“And so, until a higher degree of clarity and granularity on off-label promotions is available, the prudent course for drug and device makers is to be conservative and cautious,” Hurd writes. “Still, these cases illustrate that communications about off-label uses of drugs and devices can indeed constitute protected commercial speech, provided they constitute truthful and lawful promotions of off-label uses for FDA-approved drugs and devices. The corollary, then, is that any false and fraudulent communications about off-label uses may not merit First Amendment protection.”

For more information: www.leclairryan.com

Related Content

Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Sponsored Content | Videos | Inventory Management| February 17, 2017
The supplies you use in your cath lab are complex and very valuable.
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain
News | CT Angiography (CTA)| February 14, 2017
The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure| February 10, 2017 | Dave Fornell
In the past few years there have been a number of device therapies developed to treat heart failure (HF).
Overlay Init